-
公开(公告)号:WO2023273960A1
公开(公告)日:2023-01-05
申请号:PCT/CN2022/100140
申请日:2022-06-21
申请人: 康盈红莓(中山)生物科技有限公司
摘要: 提供了一种腺苷参与的NMN半合成方法,所述腺苷参与的NMN半合成方法包括同一反应体系下的步骤:(A)腺苷、磷酸盐以及可被酵母细胞代谢的糖类在酵母细胞的催化作用下反应生成ATP的步骤;(B)NR的酶促磷酸化步骤,对应NR和ATP在NRK的催化作用下反应生成NMN和ADP的步骤;如此以在ATP的生成与循环利用的过程中实现NMN的高效合成,在简化工艺的同时降低了排放。
-
公开(公告)号:WO2022041860A1
公开(公告)日:2022-03-03
申请号:PCT/CN2021/094309
申请日:2021-05-18
申请人: 上海迪赢生物科技有限公司
摘要: 一种用于3D喷墨法高通量核酸原位合成的功能化表面处理方法,包括如下步骤:将基底的表面进行富羟基化处理;在基底的表面修饰疏水性分子;疏水性分子不与亚磷酰胺单体反应;采用多通道压电喷墨头组件将蚀刻墨水喷射到基底表面的预设区域进行微蚀刻;蚀刻墨水采用疏水性分子反应的氟盐类化合物配制;在基底的表面修饰亲水性分子。
-
公开(公告)号:WO2021236208A1
公开(公告)日:2021-11-25
申请号:PCT/US2021/021913
申请日:2021-03-11
发明人: KIM, Youngchang , MALTSEVA, Natalia Ivanovna , JEDRZEJCZAK, Robert , JOACHIMIAK, Andrzej , WOWER, Jacek , RANDALL, Glenn
IPC分类号: A23K20/153 , C07H19/10 , C12P19/30
摘要: Provided is a method of treating a disease caused by a nidovirus that encodes Nsp15, such as a coronavirus, an arterivirus, or a torovirus, in a subject in need thereof comprising administering a therapeutically effective amount of an active agent selected from 3'-uridylic acid, 5'-uridylic acid, citrate, methacycline, meclocycline sulfosalicylate, mitoxantrone, epirubicin hydrochloride, daunorubicin hydrochloride, sorafenib, sunitinib malate, primaquine diphosphate, closantel, isopropyl ester of N4-hydroxycytidine, GpU dinucleotide or derivatives thereof, and tipiracil or N-substituted derivatives thereof. Further provided are a method of inhibiting an Nsp15 endoribonuclease of a nidovirus that encodes Nsp15 and compounds of formulas (I´) and (II´).
-
64.
公开(公告)号:WO2021146505A1
公开(公告)日:2021-07-22
申请号:PCT/US2021/013554
申请日:2021-01-15
申请人: THE FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. , MA, Teng , YUAN, Xuegang , LOGAN, Timothy
发明人: MA, Teng , YUAN, Xuegang , LOGAN, Timothy
摘要: Disclosed are compositions and methods for culturing cells in a manner that inhibits culture induced senescence. In one aspect, the methods comprise the administration of nicotinamide adenine dinucleotide (NAD) precursors to the culture. Further disclosed are NAD precursors used in the methods, comprising nicotinamide (NAM), nicotinamide mononucleotide (NMN), and/or nicotinamide riboside (NR).
-
公开(公告)号:WO2021089251A1
公开(公告)日:2021-05-14
申请号:PCT/EP2020/077396
申请日:2020-09-30
发明人: MAHOUR, Reza , REXER, Thomas F. T.
摘要: The present invention relates to an enzyme-catalyzed process for producing UDP-galactose from low-cost substrates uridine monophosphate and D-galactose in a single reaction mixture. Said process can be operated (semi)continuously or in batch mode. Said process can be extended to uridine as starting material instead of uridine monophosphate. Further, said process can be adapted to produce galactosylated molecules and biomolecules including saccharides, proteins, peptides, glycoproteins or glycopeptides, particularly human milk oligosaccharides (HMO) and (monoclonal) antibodies.
-
公开(公告)号:WO2019195240A1
公开(公告)日:2019-10-10
申请号:PCT/US2019/025323
申请日:2019-04-02
IPC分类号: C12P19/30 , C12Q1/48 , C12N9/12 , G01N33/533
摘要: Described is ELTA (Enzymatic Labeling of Terminal ADP-ribose) to label free, protein- conjugated, or nucleic acid-conjugated ADP-ribose monomer and polymers at their 2' -OH termini. When coupled with different chemical analogs, ELTA can be used for various applications including fluorescence-based biophysical measurement of PAR-protein interaction, detection of PAR length from cells, and enrichment of ADP-ribosylated peptides for mass spectrometry identification.
-
公开(公告)号:WO2018023206A1
公开(公告)日:2018-02-08
申请号:PCT/CN2016/092456
申请日:2016-07-30
申请人: 邦泰生物工程(深圳)有限公司
摘要: 一种烟酰胺磷酸核糖转移酶突变体及其应用,涉及一种通过基因定点突变的方法人工获得的烟酰胺磷酸核糖转移酶突变体及其应用。目的在于解决现有烟酰胺磷酸核糖转移酶的催化活性较低、工业应用价值较低的问题,提供了一系列烟酰胺磷酸核糖转移酶突变体,以及相应的核苷酸序列、表达载体和活体细胞,这些突变体以烟酰胺和PRPP为底物的酶催化活性是其亲本的1.2-6.9倍,可应用在制备烟酰胺单核苷酸的工艺中。
-
公开(公告)号:WO2017153266A1
公开(公告)日:2017-09-14
申请号:PCT/EP2017/054989
申请日:2017-03-03
申请人: PROSOL S.P.A.
摘要: Process for the production of RNA from microbial cells,which comprises steps of treating such cells to release the cell content thereof, including RNA; separating the RNA from other soluble cellular compounds via an osmotic process by the use of semi-permeable membranes and concentration, obtaining a retentate enriched in RNA; adjusting the retentate pH to a value between 2 and 3, thus causing the precipitation of RNA, and recovering the precipitated RNA by filtration or centrifugation, wherein the aforesaid osmotic process is a diafiltration and prior to adjusting the retentate pH to a value between 2 and 3, a salting out step is performed at a pH between 3.5 and 5.0 with ensuing precipitation of the proteins that are present in the retentate.
摘要翻译: 从微生物细胞产生RNA的方法,其包括处理这些细胞以释放其细胞含量(包括RNA)的步骤; 通过使用半渗透膜和浓缩的渗透过程将RNA与其他可溶性细胞化合物分离,获得富含RNA的滞留物; 将滞留物pH调节至2至3之间的值,从而引起RNA的沉淀,并且通过过滤或离心回收沉淀的RNA,其中上述渗透过程是渗滤,并且在将渗余物pH调节至2和3之间的值之前 在图3中,盐析步骤在3.5和5.0之间的pH下进行,随后沉淀存在于渗余物中的蛋白质。 p>
-
公开(公告)号:WO2017022768A1
公开(公告)日:2017-02-09
申请号:PCT/JP2016/072675
申请日:2016-08-02
申请人: 興人ライフサイエンス株式会社
IPC分类号: A23L31/15 , A61K31/706 , A61K36/06 , A61P3/00 , A61P3/10 , A61P9/10 , A61P25/28 , A61P43/00 , C12P19/30
CPC分类号: A23L31/15 , A61K31/706 , A61K36/06 , C12P19/30
摘要: 【課題】 食経験のある安全な酵母からβ‐ニコチンアミドモノヌクレオチド(β-NMN)を含有した酵母エキスを得ること、酵母由来のβ-NMN組成物を得ることを課題とする。 【解決手段】 酵母から特定温度、pH、で酵母エキスを抽出することで、β-NMNを含有した酵母エキスを得られることを見出した。また、β-NMN含有酵母エキス又は酵母抽出液からβ-NMNを精製することで、酵母由来のβ-NMN含有組成物を得ることができる。
摘要翻译: [问题]从已经长时间食用的安全酵母获得含有β-烟酰胺单核苷酸(β-NMN)的固体酵母提取物。 得到来源于酵母的β-NMN组合物。 [解决方案]发现通过在特定温度和特定pH值下提取酵母可以获得含有β-NMN的固体酵母提取物。 通过从含有β-NMN的固体酵母提取物或液体酵母提取物中纯化β-NMN,可以得到衍生自酵母的β-NMN组合物。
-
公开(公告)号:WO2015164336A3
公开(公告)日:2016-12-01
申请号:PCT/US2015026817
申请日:2015-04-21
发明人: HUANG DEJIAN , OU BOXIN , GALVIN JIM , BYRNE EAMONN
CPC分类号: C12N15/1003 , C12N15/10 , C12P19/30 , C12P19/305 , C12P19/32
摘要: The invention provides novel and improved methods that allow effective capture of valuable active ingredients in biomass (e.g., DDGS) at cost-effective commercial scale. The invention also provides novel compositions of active ingredients with unique properties (e.g., nutritional values and enhanced bioavailability).
摘要翻译: 本发明提供新颖和改进的方法,其允许在成本有效的商业规模下有效捕获生物质(例如DDGS)中的有价值的活性成分。 本发明还提供具有独特性质(例如营养价值和增强的生物利用度)的活性成分的新组合物。
-
-
-
-
-
-
-
-
-